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THE COMPARATIVE ACTION OF DICUMAROL AND OF
PHENYLINDANEDIONE ON THE COAGULASE REACTING
FACTOR AND ON PROTHROMBIN*
MORRIS TAGERt
Recent studies' have established the presence of a factor ("activator,"
Coagulase-reacting factor, or CRF) in plasma which is required for the
coagulation of blood by staphylocoagulase. Maximum CRF activity resides
in the globulin fractions of plasma, and separation from prothrombin is best
achieved by repeated Seitz filtration.10 The filtration involves different rates
of adsorption of prothrombin and CRF," so that when the filtrate is essen-
tially devoid of prothrombin it still may possess substantial CRF activity.
Efforts to identify CRF with factors at present known to participate in
physiological clotting of blood have been unsuccessful,10'11 and the hypothesis
has been proposed that the coagulase-CRF reaction bypasses the currently
accepted pathways functioning in physiological clotting. The many points of
resemblance between prothrombin and CRF, as well as the differences, have
been discussed elsewhere."11 Duthie and Lorenz' find it tempting to consider
prothrombin and CRF as identical. They point to similarities in physical
properties, parallel losses of both prothrombin and CRF when prothrombin
is converted to thrombin, to localization in comparable fractions of plasma,
and to the finding that the concentration of both prothrombin and CRF
decrease "almost pari passu" following dicumarol administration in rabbits.
To explain the separation of CRF from prothrombin by Seitz filtration,
they suggest that this procedure may not actually remove prothrombin, but
that the physical structure of prothrombin is so altered that it can no longer
be converted to thrombin while it continues to function as a coagulase
''activator."
The observations of Duthie and Lorenz that dicumarol administration
depresses CRF activity have been confirmed in this laboratory, both in
rabbits and in patients undergoing dicumarol therapy for thrombotic disease.
On the other hand, Miale' failed to note any effect on CRF levels of plasma
of 21 patients on a dicumarol regime. The present study was undertaken to
resolve this conflict, particularly since it seemed possible that a detailed
quantitative analysis of the effect of dicumarol and related compounds on
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prothrombin and on CRF might contribute to a better understanding of the
relation of these factors to each other.
MATERIALS AND METHODS
Coagulase-a water clear, purified product prepared from Staphylococcus aureus
#104, as previously described.'
Fibrinogen-Armour's bovine Fraction I, used in a concentration of 300 mgm. per
cent in buffered saline at pH 7.2.
Plasma. Rabbit plasmas were collected by venipuncture in an excess of sodium
citrate, care being taken to avoid clotting and to maintain a constant citrate to plasma
volume ratio. Plasma dilutions were made in physiological saline with 2 mgm. of
bovine albumin (Armour's Fraction V) per ml.
General procedure for the titration of CRF. To obtain the reference 100 per cent
standard, plasma samples were obtained from each rabbit before drug administration,
dilutions of 1:100, 1: 200, 1: 400, and 1: 800 were prepared in saline-albumin. To
0.2 ml. lots of plasma were added 0.2 ml. of fibrinogen in pyrex test tubes 7 x 12 mm.
in size. Two-tenths ml. of coagulase were forcibly blown into each tube at the instant
of starting the stop watch. The tubes were removed from the 370 C. water bath and
continuously observed with a 2X magnifying lens using a constant fluorescent light
source. The appearance of the first wisp of fibrin, or of definite flocculation, was taken
as the clotting time. Titrations were carried out in duplicate, and checks within 3-5
seconds generally obtained at the more concentrated ranges of plasma. The clotting
times were plotted arithmetically, and the per cent CRF activity of post-drug plasma
samples was computed from these curves. In the titrations of post-drug samples,
dilutions of 1: 100 and 1: 200 only were tested. Controls of coagulase and fibrinogen
only, as well as of plasma and fibrinogen, were simultaneously carried out, and
remained negative.
Thromboplastin. Acetone extracted rabbit brain was prepared, or the commercially
available Bacto-thromboplastin (Difco) was used.
Bovine plasma. Fresh beef plasma, obtained from the slaughter house, was filtered
five times through EK Seitz pads. No clotting occurred upon the addition of thrombo-
plastin and calcium within 20 minutes. An equal volume of 0.6% imidazol buffer was
added, and the plasma further diluted with an equal volume of distilled water, the final
pH being adjusted to 7.2.
Prothrombin determination. The method of Ware and Stragnell' was adopted with
minor modifications. In essence, this is a one-stage technique involving the use of
diluted plasma, and providing a constant supply of accelerator globulin and fibrinogen
by the addition of prothrombin-free bovine plasma to the reaction mixture. Plotted
logarithmically, a straight line generally is obtained from which the per cent activity
of post-drug samples may be directly computed.
Procedure: Citrated rabbit plasma dilutions were prepared of 100, 80, 60, and 20%
concentration respectively, taking the 1: 10 dilution in distilled water as the initial
100% value. One-tenth ml. of the appropriate plasma dilutions were dispensed in 7x 12
mm. pyrex tubes, 0.1 ml. of the prothrombin-free bovine plasma and 0.1 ml. of thrombo-
plastin were added. After an incubation period of two minutes at 37° C., 0.1 ml. of
0.05 M CaCl2 was forcibly blown in with a 0.1 ml. serological pipette at the instant of
setting the stop watch into motion. The tubes were observed under the same conditions
as described above for CRF titration, and were gently tilted at room temperature to
note the first appearance of fibrin. Except at the more prolonged clotting times,
duplicate checks within two seconds were generally obtained. The test differed from
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the Ware and Stragnell technique in minor detail: the prothrombin-free bovine plasma
was citrated rather than oxalated, and essentially freed of prothrombin by repeated
Seitz filtration rather than by combined Seitz filtration and by barium sulfate adsorb-
tion. No heparin was added to the anticoagulant, but the higher concentration of citrate
used to prevent the clotting of rabbit plasma necessitated the use of a higher
concentration of calcium chloride.
Dicumarol (bishydroxycoumarin, Abbott). The tablets were ground in a mortar and
pestle with propylene glycol1 to form a homogeneous suspension, and the drug was
administered into the upper leg muscles of rabbits.
Phenylindanedione (PID)-obtained through the co6peration of Dr. E. A. Sharp
and Dr. J. E. Gajewski of Parke, Davis and Co. was prepared and administered
similarly to dicumarol.
Mephyton (Vitamin K1 Merck, 2-Methyl-3-phytyl-1,4-naphthoquinone). The emul-
sion, containing 50 mgm. per ml., was slowly administered intravenously, without
untoward effect.
Rabbits. Adult domestically raised New Zealand white rabbits were used, ranging in
weight from 3.09 to 5.02 kilograms.
RESULTS
The effect of dicumarol and of mephyton on CRF and on prothrombin of
rabbits. In a preliminary titration (Table 1) 7 rabbits received intra-
muscularly dicumarol, rabbits #4, 5 and 12, 10 mgm./kg. and rabbits #3,
10, 11, and 14, 25 mgm./kg. It is readily apparent that dicumarol is effective
in depressing both prothrombin and CRF. However, in most animals there
was no close correspondence in the effects produced on prothrombin and on
CRF, with the reduction in prothrombin being generally more rapid and
severe than in CRF. Individual differences in the response of the rabbits
overshadowed the dose of dicumarol administered, since there was no con-
sistent increase in clotting times with the higher level of the drug. Rabbit
#12 was unique in showing no reduction in CRF and only a minimal
prothrombin effect, confirmed by a subsequent titration.
Since the preliminary titration did not reveal any close parallelism in
dicumarol action on prothrombin and on CRF, it was deemed of interest to
compare the response of these factors to a substance like mephyton known
to combat the anticoagulant effect of dicumarol and similar agents. Accord-
ingly, after a rest period of a month, rabbits #4, 5, 10, and 11 were given
25 mgm./kg. of dicumarol, and at 72 hours from 25 to 35 mgm. of mephyton
were injected intravenously in rabbits #4, 5, and 10, respectively. The
results are summarized in Table 2, and expressed in both per cent of activity
and in the actual clotting times obtained. Inspection of the data, especially
when one compares the 144-hour post-dicumarol levels with those at
the same time in Table 1, clearly indicates the effectiveness of mephyton
in reversing the dicumarol effect on CRF. The prothrombin titers, how-
ever, increased far more rapidly, and the apparent increase in prothrom-
bin content was evident even within four hours following mephyton
administration.
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The effect of phenylindanedione and of mephyton on CRF and prothrom-
bin times in rabbits. Phenylindanedione (PID)4'9 has recently been
proposed as an anticoagulant which might reduce some of the hazards of
dicumarol because of more rapid recovery after oral administration. It
TABLE 2
THE EFFECT OF MEPHYTON ON PROTHROMBIN AND CRF AFTER
DICUMAROL ADMINISTRATION
Rabbit $
4 5 10 11 7
Dicumarol Dicumarol Dicumarol
+ + + Dicumarol Bleeding
Time in mephyton mephyton mephyton only only
hours Pr CRF Pr CRF Pr CRF Pr CRF Pr CRF
Pre-drug % 100 100 100 100 100 100 100 100 100 100
control c.t. sec. 29 85 33 95 27 68 23.5 97 23 65
-72 post % 7 1 1.5 75 19 14 13 54 99 100
dicumarol c.t. sec. 210 253 325 110 73 190 101 160 23.5 65
4 post % 48 13 33 45 36 23 11 57 ... ...
mephyton, c.t. sec. 50 169 137 136 48 142 106 155 ......
76 post
dicumarol
24 post % 135 40 85 50 135 68 11 49 110 90
mephyton, c.t. sec. 24 132 41 125 23 87 107 169 21.5 112
96 post
dicumarol
48 post % 88 48 88 100 145 100 23 46 ... ...
mephyton, c.t. sec. 32 125 39 95 21 68 63 177 ......
120 post
dicumarol
72 post % 100 85 100 100 140 87 23 31 ... ...
mephyton, c.t. sec. 29 95 33 95 22.5 77 63 222 ......
144 post
dicumarol
Dicumarol: 25 mgm./kg. i.m.
Mephyton: 25 mgm. i.v., rabbits #4 and 5; 35 mgm. i.v., rabbit #10.
Each clotting time-average of two titrations.
seemed of interest, therefore, to determine whether CRF is also affected by
this drug, and whether this action is reversible by mephyton. Six rabbits
were given PID intramuscularly in a dose of 75 mgm./kg. (Table 3). In
spite of this excessive dose, parenterally administered, the reduction in pro-
thrombin activity was not as drastic as with dicumarol, and by 60 hours,
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most of the animals were showing either rising titers or had returned to
normal levels or beyond. The CRF reduction was not excessive either, was
generally less marked than the prothrombin response, and was usually
associated with a less rapid trend toward recovery at 60 hours. As in the
experiments with dicumarol, rabbit #12 responded very poorly, with
relatively slight action on prothrombin and on CRF alike.
TABLE 4
THE EFFECT OF MEPHYTON ON PROTHROMBIN AND CRF AFTER
PHENYLINDANEDIONE ADMINISTRATION
Rabbit $
2 4 8 13
PID PID PID
+ + + PID
Time in mephyton mephyton mephyton only
hours Pr CRF Pr CRF Pr CRF Pr CRF
Pre-drug 100 100 100 100 100 100 100 100
control c.t. sec. 23.5 86 21.5 79 23 76 28.5 85
18 post % 48 85 50 78 28 18 80 87
PID c.t. sec. 34 92 33.5 88 56 205 32.5 93
4 post % 80 75 105 99 62 49 43 84
mephyton, c.t. sec. 26 97 20 80 33 100 43 95
22 post
PID
24 post 110 100 105 99 82 62 26 48
mephyton, c.t. sec. 22 86 20.5 80 26.5 90 58 130
46 post
PID
PID-75 mgm./kg. i.m.
Mephyton-40 mgm. i.v.
Each clotting time-average of two titrations.
When mephyton was administered, in a dose of 40 mgm. per rabbit intra-
venously, prompt reversal of the anticoagulant effect of PID was noted
(Table 4). While the number of observations was too few to permit any
generalization, and allowing for the differences in the 18-hour post-PID
levels of prothrombin and CRF, a fairly close parallelism of action was
evident.
DISCUSSION
The data presented indicate that, like prothrombin, the coagulase-
reacting factor is depressed by the administration of dicumarol and of
phenylindanedione. Similarly, Vitamin K1 (mephyton) effectively counter-
acts this depressing action on both prothrombin and CRF. If one adopts the
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view that these anticoagulants act by interfering with the synthesis of pro-
thrombin in the liver from Vitamin K-like precursors, then these results may
be interpreted as pointing to a structural similarity between the precursors of
prothrombin and of CRF. The close relationship between prothrombin and
CRF is further suggested by the response of rabbit #12. In this animal,
both anticoagulants exerted minimal effects on prothrombin and on CRF
alike.
In no sense, however, should these data be construed as implying an
identity of structure of.prothrombin and of CRF. It has recently been shown
that dicumarol has an effect also on prothrombin activators,2 hence its
action cannot any longer be regarded as specifically interfering with pro-
thrombin synthesis only. Even pari passu action of all the agents tested
would not establish the identity of prothrombin and CRF, since this might
represent similar action on closely related substances rather than on one
factor. Actually, pari passu effects on prothrombin and on CRF were by no
means consistently observed, even when allowances were made for differ-
ences in the sensitivity of the tests. On the contrary, frequently a sharp
divergence in the prothrombin and CRF clotting times was observed. It is
hoped that studies in progress on the chemical purification of CRF may
yield more definitive data on the problem of its relation to prothrombin.
SUMMARY
A comparative study of the action of dicumarol and of phenylindanedione
on the coagulase reacting factor and on prothrombin is presented.
Intramuscular administration of dicumarol and of PID in rabbits reduces
the plasma levels of CRF as well as of prothrombin.
The response of CRF and of prothrombin to the anticoagulants does not
consistently proceed pari passu.
Vitamin K1 (mephyton) successfully reverses the action of both anti-
coagulants on CRF and on prothrombin.
The implications of these observations on the problem of the relationship
of CRF to prothrombin are discussed.
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